Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Copley Scientific has launched a new apparatus designed specifically for dissolution testing of inhaled drug formulations. Based on a concept developed by Jason McConville and his team at the College of Pharmacy, University of Texas, the new NGI dissolution cup and membrane holder enables dissolution testing of size-fractionated particles selected from the emitted dose.
Subscribe to our email newsletter
The company claims that it is simple to use and employs analytical methodology based on established pharmacopoeial techniques for transdermal patches. It provides information that allows developers to more closely tailor inhaled drug delivery.
Copley Scientific said that the launch underlines its effort to commercialising new analytical techniques for inhaled product testing and to provide best tools for development and QC.
In dissolution testing for inhaled drugs, the respirable portion of the emitted dose is of primary interest. The new solution from the company addresses this by integrating conventional tablet dissolution testing equipment within the Impactor (NGI), a system used routinely for aerodynamic particle size measurement to size fractionate a sample.
The NGI dissolution cup fits into a conventional NGI cup tray but has a 50mm removable insert in the impaction area, allowing the collection of particles lying in a specific size fraction. The collected sample is tested in a dissolution tester using a procedure very similar to the ‘Paddle over Disc’ technique, described in the pharmacopoeia for transdermal patches. Copley Scientific also offers a similar solution for use with the Andersen Cascade Impactor.